The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
about
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomasTyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancerAXL kinase as a novel target for cancer therapyNeuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid raftsThe Receptor Tyrosine Kinase AXL in Cancer ProgressionMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyG protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.AXL mediates resistance to cetuximab therapyDiversification of TAM receptor tyrosine kinase functionDifferential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Axl as a mediator of cellular growth and survivalOseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinomaNovel points of attack for targeted cancer therapy.The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaTherapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerTargeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancerAxl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.MenaINV mediates synergistic cross-talk between signaling pathways driving chemotaxis and haptotaxis.Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor ResistanceBypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer--culprits for resistance to EGFR inhibitors?Discoidin domain receptors: a proteomic portrait.The role of phospholipase Cγ1 in breast cancer and its clinical significance.AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.
P2860
Q24336818-00FD09DC-89F0-48AB-A64F-4AC2BC313E06Q26823237-9FDFC5ED-3B55-4CB4-986A-A7FE66F9D23BQ26863442-11C0FB50-158E-4853-B560-366799C795B3Q27319837-9A9D787B-C4AD-4851-B73E-8477E9F5DE60Q28068756-4EC6A24A-8190-4788-86D6-704E75D461D4Q28070028-5EE8E3AA-285C-433F-B2BD-AF6C26A88FA2Q28073335-9F714BBF-829F-4702-96F7-4DC328BAEBACQ30845910-012415FF-62F6-4F0C-98E1-E6BDC632CB95Q33847457-10376DB2-B31E-46A8-BA57-F7E5FCD667DFQ33910532-BD155921-1A5A-4147-B4D1-DEE697378161Q34204829-452441E8-A9E1-4C1F-B94E-BF451F583790Q34214465-DC90CD8C-A501-4A54-AAA6-CE5873D5D19CQ34390266-29EFF998-98BD-41DC-8C47-5CFA241D5D43Q34439798-982B2CC1-01B4-47EF-8875-B2850B661E9FQ34619118-262ABB40-BB5E-4887-96FB-6B5ACD0E64CFQ34700909-4063523E-B53B-4360-97CE-E2F5E16D7E5FQ35023279-C170A755-8D55-4379-ADF1-3DAD7FAA14AFQ35149569-3AF27B98-0BC8-4F32-A25C-3480F2FC99E0Q35341639-B95A6AFA-B3F1-4334-A183-825EA46918B9Q35600765-5E8102FB-1A7A-4014-B2B8-649C6DA6EB6AQ35625440-E5833FA9-0138-4F8E-82A7-0AA98647A88DQ35657842-8776BA43-3FCF-40E0-9F0E-9DDBC16AAC05Q35832938-1F31B01F-2B7A-4335-B7C2-241239C19CDAQ36021012-7B7CA1FC-7869-413D-B2A0-975D0EADA3EAQ36097941-B12DF844-EFFE-41A6-86F9-2824996C9083Q36214760-DBA8A368-DFDA-4FA4-94F7-FBBE8D33B654Q36436763-E07C94E1-67FA-4DBB-8509-3CB28432BF01Q36557240-DE784124-DE7D-4124-A021-DA712859B877Q36839141-8949E652-A756-4B8B-B625-8392A8B08FDFQ36970393-385FA882-CD6C-45AF-8F1F-92A6B893F41BQ37233198-38145E99-E011-423B-956D-E5AB4FBABD22Q37274810-E13A7E85-8491-41BF-A8DB-C206DD711E28Q37338247-990A1D41-42EC-4A7B-B446-ADCE65BE680FQ37380418-8BAC7F76-3E3B-4CF1-BFB9-D43AA674BE64Q37421439-620E5E8B-C28B-4EB8-8CE4-7D8C3BBA7FCBQ37665524-70D1AFBE-D0ED-47BA-8717-21E376145B19Q37690362-D08A3313-A326-40A0-B2AB-161B1510B539Q38202550-3FCEBFC5-AD58-4404-A8C4-F4A5CCFAEDD6Q38638852-D670A275-11F9-4840-A8C4-AE617F774699Q38672995-44FA5272-3F79-4F53-9B15-A17F6C8A9CBA
P2860
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The receptor AXL diversifies E ...... -negative breast cancer cells.
@en
The receptor AXL diversifies E ...... -negative breast cancer cells.
@nl
type
label
The receptor AXL diversifies E ...... -negative breast cancer cells.
@en
The receptor AXL diversifies E ...... -negative breast cancer cells.
@nl
prefLabel
The receptor AXL diversifies E ...... -negative breast cancer cells.
@en
The receptor AXL diversifies E ...... -negative breast cancer cells.
@nl
P2860
P50
P1433
P1476
The receptor AXL diversifies E ...... -negative breast cancer cells.
@en
P2093
Frank B Gertler
P2860
P356
10.1126/SCISIGNAL.2004155
P577
2013-08-06T00:00:00Z